Home/LENZ Therapeutics/M. (Rienk) van Genderingen
M(

M. (Rienk) van Genderingen

Chief Financial Officer

LENZ Therapeutics

Therapeutic Areas

LENZ Therapeutics Pipeline

DrugIndicationPhase
LNZ100 (aceclidine)PresbyopiaPhase 3
LNZ101 (aceclidine + brimonidine)PresbyopiaPhase 3